{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:56:43Z","timestamp":1760147803144,"version":"build-2065373602"},"reference-count":40,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Opioid analgesics, which are used for cancer-related pain management, cause opioid-induced constipation (OIC). Naldemedine, a peripheral opioid receptor antagonist, is an OIC-modifying agent, but no focused efficacy and safety analysis has been conducted for its use in hepatobiliary pancreatic cancers. We performed a multi-institutional study on the efficacy and safety of naldemedine in patients with hepatobiliary pancreatic cancer using opioids in clinical practice. Materials and Methods: We retrospectively evaluated patients with hepatobiliary pancreatic cancer (including liver, biliary tract, and pancreatic cancers) treated with opioids and naldemedine during hospitalization at ten institutions in Japan from June 2017 to August 2019. We assessed the frequency of bowel movements before and after the initiation of naldemedine therapy. Responders were defined as patients who defecated \u22653 times\/week, with an increase from a baseline of \u22651 defecations\/week over seven days after the initiation of naldemedine administration. Results: Thirty-four patients were observed for one week before and one week after starting naldemedine. The frequency of bowel movements increased by one over the baseline frequency or to at least thrice per week in 21 patients. The response rate was 61.7% (95% confidence interval: 45.4\u201378.0%). The median number of weekly bowel movements before and after naldemedine treatment was 2 (range: 0\u20139) and 6 (range: 1\u201317), respectively, in the overall population (n = 34); the increase in the number of bowel movements following naldemedine administration was statistically significant (Wilcoxon signed-rank test, p &lt; 0.0001). Diarrhea was the predominant gastrointestinal symptom, and 10 (29.4%) patients experienced grade 1, grade 2, or grade 3 adverse events. The only other adverse event included fatigue in one patient; grade 2\u20134 adverse events were absent. Conclusions: Naldemedine is effective, and its use may be safe in clinical practice for patients with hepatobiliary pancreatic cancer receiving opioid analgesics.<\/jats:p>","DOI":"10.3390\/medicina59030492","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T04:57:38Z","timestamp":1677733058000},"page":"492","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Retrospective Study of the Efficacy and Safety of Naldemedine for Treatment of Opioid-Induced Constipation in Patients with Hepatobiliary Pancreatic Cancer"],"prefix":"10.3390","volume":"59","author":[{"given":"Teruhiko","family":"Kamiya","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Tatebayashi Kosei General Hospital, 262-1 Narushima, Tatebayashi 374-8533, Gunma, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-4255","authenticated-orcid":false,"given":"Hisao","family":"Imai","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Gunma Prefectural Cancer Center, 617-1 Takahayashi-nishi, Ota 373-0828, Gunma, Japan"},{"name":"Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka 350-1298, Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2444-5974","authenticated-orcid":false,"given":"Yukiyoshi","family":"Fujita","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Gunma Prefectural Cancer Center, 617-1 Takahayashi-nishi, Ota 373-0828, Gunma, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriko","family":"Hiruta","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Gunma Prefectural Cancer Center, 617-1 Takahayashi-nishi, Ota 373-0828, Gunma, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Masuno","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Fujioka General Hospital, 813-1 Nakagurisu, Fujioka 375-8503, Gunma, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Kiryu Kosei General Hospital, 6-3 Orihime, Kiryu 376-0024, Gunma, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Haramachi Red Cross Hospital, 698 Haramachi, Higashiagatsuma-machi, Agatsuma-gun 377-0882, Gunma, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Sandoh","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Ota Memorial Hospital, 455-1 Oshima, Ota 373-8585, Gunma, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Takei","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Tone Central Hospital, 910-1 Numasu, Numata 378-0012, Gunma, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Arai","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Gunma Saiseikai Maebashi Hospital, 564-1 Kamishinden, Maebashi 371-0821, Gunma, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Nishiba","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Japan Community Health Care Organization (JCHO) Gunma Chuo Hospital, 1-7-13 Kouun, Maebashi 371-0025, Gunma, Japan"},{"name":"Laboratory of Clinical Pharmacy, Faculty of Pharmacy, Takasaki University of Health and Welfare, 37-1 Nakaorui, Takasaki 370-0033, Gunma, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junnosuke","family":"Mogi","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Hidaka Hospital, 886 Nakao-machi, Takasaki 370-0001, Gunma, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Koizuka","sequence":"additional","affiliation":[{"name":"Division of Palliative Care, Gunma Prefectural Cancer Center, 617-1 Takahayashi-nishi, Ota 373-0828, Gunma, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taeko","family":"Saito","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Gunma Prefectural Cancer Center, 617-1 Takahayashi-nishi, Ota 373-0828, Gunma, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Obayashi","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacy, Faculty of Pharmacy, Takasaki University of Health and Welfare, 37-1 Nakaorui, Takasaki 370-0033, Gunma, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5548-7686","authenticated-orcid":false,"given":"Kyoichi","family":"Kaira","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka 350-1298, Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Minato","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Gunma Prefectural Cancer Center, 617-1 Takahayashi-nishi, Ota 373-0828, Gunma, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4103\/eus.eus_20_19","article-title":"Recent developments in hepatopancreatobiliary EUS","volume":"8","author":"Cazacu","year":"2019","journal-title":"Endosc. Ultrasound"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.4103\/eus.eus_16_18","article-title":"Initial experience with EUS-guided microbiopsy forceps in diagnosing pancreatic cystic lesions: A multicenter feasibility study (with video)","volume":"7","author":"Kovacevic","year":"2018","journal-title":"Endosc. Ultrasound"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4103\/eus.eus_16_19","article-title":"Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic cancer (PEACE): A study protocol","volume":"8","author":"Saftoiu","year":"2019","journal-title":"Endosc. Ultrasound"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","article-title":"Hepatocellular carcinoma","volume":"2","author":"Llovet","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Expert consensus document: Cholangiocarcinoma: Current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","article-title":"Pancreatic cancer","volume":"2","author":"Kleeff","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"iv166","DOI":"10.1093\/annonc\/mdy152","article-title":"Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines","volume":"29","author":"Fallon","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12094-017-1791-2","article-title":"SEOM clinical guideline for treatment of cancer pain (2017)","volume":"20","author":"Jara","year":"2018","journal-title":"Clin. Transl. Oncol."},{"key":"ref_10","first-page":"CD003868","article-title":"Oral morphine for cancer pain","volume":"4","author":"Wiffen","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_11","first-page":"CD012592","article-title":"Opioids for cancer pain\u2014An overview of Cochrane reviews","volume":"7","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1526-4637.2008.00495.x","article-title":"The prevalence, severity, and impact of opioid-induced bowel dysfunction: Results of a US and European Patient Survey (PROBE 1)","volume":"10","author":"Bell","year":"2009","journal-title":"Pain Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/AJP.0b013e318237d626","article-title":"A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction","volume":"28","author":"Ishihara","year":"2012","journal-title":"Clin. J. Pain"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel Disorders","volume":"150","author":"Mearin","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_15","first-page":"CD011056","article-title":"Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain","volume":"5","author":"Wiffen","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1177\/0269216311404273","article-title":"Management of opioid-induced nausea and vomiting in cancer patients: Systematic review and evidence-based recommendations","volume":"25","author":"Laugsand","year":"2011","journal-title":"Palliat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1111\/pme.12724","article-title":"Opioid-induced constipation among patients with chronic noncancer pain in the United States, Canada, Germany, and the United Kingdom: Laxative use, response, and symptom burden over time","volume":"16","author":"Coyne","year":"2015","journal-title":"Pain Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s00134-015-4050-4","article-title":"Constipation is independently associated with delirium in critically ill ventilated patients","volume":"42","author":"Smonig","year":"2016","journal-title":"Intensive Care Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.5055\/jom.2015.0282","article-title":"Impact of constipation on opioid therapy management among long-term opioid users, based on a patient survey","volume":"11","author":"Gupta","year":"2015","journal-title":"J. Opioid Manag."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1002\/cam4.2341","article-title":"Incidence of opioid-induced constipation in Japanese patients with cancer pain: A prospective observational cohort study","volume":"8","author":"Tokoro","year":"2019","journal-title":"Cancer Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e13367","DOI":"10.1111\/nmo.13367","article-title":"Reduction in pain: Is it worth the gain? The effect of opioids on the GI tract","volume":"30","author":"Nee","year":"2018","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_22","first-page":"345","article-title":"Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction","volume":"7","author":"Poulsen","year":"2014","journal-title":"Clin. Exp. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/MEG.0000000000000574","article-title":"Opioid-induced bowel dysfunction in healthy volunteers assessed with questionnaires and MRI","volume":"28","author":"Nilsson","year":"2016","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s40265-019-01160-7","article-title":"Naldemedine: A review in opioid-induced constipation","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1200\/JCO.2017.73.0853","article-title":"Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer","volume":"35","author":"Katakami","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/annonc\/mdy118","article-title":"Randomized phase III and extension studies: Efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer","volume":"29","author":"Katakami","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Hiruta, E., Fujita, Y., Imai, H., Masuno, T., Yamazaki, S., Tanaka, H., Kamiya, T., Ito, M., Takei, S., and Matsuura, M. (2021). Real-world patient characteristics and treatment patterns of naldemedine for the treatment of opioid-induced constipation in patients with cancer: A multicenter retrospective chart review study. Medicina, 57.","DOI":"10.3390\/medicina57111233"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Nishiba, H., Imai, H., Fujita, Y., Hiruta, E., Masuno, T., Yamazaki, S., Tanaka, H., Kamiya, T., Ito, M., and Takei, S. (2022). Efficacy and safety of naldemedine for patients with cancer with opioid-induced constipation in clinical practice: A real-world retrospective study. J. Clin. Med., 11.","DOI":"10.3390\/jcm11092672"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1007\/s00520-021-06299-2","article-title":"Effectiveness of naloxegol in patients with cancer pain suffering from opioid-induced constipation","volume":"29","author":"Lemaire","year":"2021","journal-title":"Support. Care Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11095-018-2501-7","article-title":"Population pharmacokinetics and exposure-response relationships of naldemedine","volume":"35","author":"Kubota","year":"2018","journal-title":"Pharm. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e000527","DOI":"10.1136\/esmoopen-2019-000527","article-title":"Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: A pooled, subgroup analysis of two randomised controlled studies","volume":"4","author":"Osaka","year":"2019","journal-title":"ESMO Open"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1200\/JCO.2016.70.8453","article-title":"Phase IIb, randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer","volume":"35","author":"Katakami","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S908","DOI":"10.21037\/jtd.2016.05.20","article-title":"Lung cancer in elderly patients","volume":"8","author":"Venuta","year":"2016","journal-title":"J. Thorac. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40266-020-00753-2","article-title":"Safety and efficacy of naldemedine for the treatment of opioid-induced constipation in patients with chronic non-cancer pain receiving opioid therapy: A subgroup analysis of patients >\/= 65 years of age","volume":"37","author":"Wild","year":"2020","journal-title":"Drugs Aging"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/j.1572-0241.2001.03536.x","article-title":"Narcotic analgesic effects on the sphincter of Oddi: A review of the data and therapeutic implications in treating pancreatitis","volume":"96","author":"Thompson","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1053\/gast.2002.31037","article-title":"Opioid agonists inhibit excitatory neurotransmission in ganglia and at the neuromus3cular junction in Guinea pig gallbladder","volume":"122","author":"Guarraci","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_37","first-page":"1463","article-title":"Effect of sequential administration of an opioid and cholecystokinin on gallbladder ejection fraction: Brief communication","volume":"47","author":"Krishnamurthy","year":"2006","journal-title":"J. Nucl. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1111\/1759-7714.14557","article-title":"A retrospective study of the efficacy and safety of naldemedine for opioid-induced constipation in thoracic cancer patients","volume":"13","author":"Imai","year":"2022","journal-title":"Thorac. Cancer"},{"key":"ref_39","first-page":"1837","article-title":"Opioid-induced constipation and bowel dysfunction: A clinical guideline","volume":"18","author":"Bassotti","year":"2017","journal-title":"Pain Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3111\/13696990903430481","article-title":"Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation","volume":"12","author":"Rentz","year":"2009","journal-title":"J. Med. Econ."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/3\/492\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:46:05Z","timestamp":1760121965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/3\/492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["medicina59030492"],"URL":"https:\/\/doi.org\/10.3390\/medicina59030492","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2023,3,2]]}}}